PMVP PMV Pharmaceuticals, Inc.

Overview and Growth

In fiscal 2025, PMV Pharmaceuticals, Inc. reported net loss of $77.74M. Diluted earnings per share were -$1.48, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 52.54M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Diluted shares moved 1.9% from 51.58M in fiscal 2024, leaving the current share base higher year over year. At period end, total assets were $116.56M, framing the scale of the company’s operating and financing commitments.

Profitability

Operations produced a $86.21M operating loss before non-operating and tax effects. The company ended the period with a net loss of $77.74M, extending the operating result through all remaining items. The company reported negative EBITDA of $86.07M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The pretax result was a loss of $79.91M, establishing the deficit before tax effects. An income-tax benefit of $2.17M improved the final result relative to pretax income or loss. The net loss equaled 74.2% of period-end equity, showing the deficit relative to book capital. The net loss equaled 66.7% of period-end assets, showing the deficit relative to the asset base. The net loss widened to $77.74M from $58.71M in fiscal 2024.

Liquidity and Capital Structure

The company held $116.56M of assets against $11.85M of liabilities and $104.71M of equity, revealing how the asset base was financed. At period end, current assets of $115.23M compared with current liabilities of $11.41M, defining the company’s short-term resource position. Current assets covered current liabilities by 10.09x, leaving a positive buffer for near-term obligations. The company held $37.98M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 332.7% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 89.8%, placing book capital against the total resource base. Liabilities represented 10.2% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 32.6% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 39.1% from $191.29M in fiscal 2024, leaving current total assets lower year over year. Book equity was 40.5% lower than fiscal 2024 equity of $176.08M, showing how shareholder capital changed year over year. Compared with $40.88M in fiscal 2024, the current cash balance moved 7.1% and finished lower.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $73.58M, rather than cash generation from operations. Capital spending of $29.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. The company recorded a $73.61M cash deficit after capital spending for the period. The cash deficit after capital spending represented 63.1% of the period-end asset base. The operating cash outflow widened to $73.58M from $51.28M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.